ArticleCardiovascular therapeutics2025
The Application Value of Brain Natriuretic Peptide in the Prognostic Evaluation of Patients With Chronic Left Heart Failure.
Article in Cardiovascular therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study explores the predictive utility of brain natriuretic peptide (BNP) levels in assessing outcomes for patients with chronic left heart failure (LHF). A cohort of 59 patients diagnosed with chronic LHF was compared to 59 healthy controls. BNP levels, alongside other cardiac function parameters, such as left ventricular ejection fraction (LVEF) and left ventricular end-systolic dimension (LVESD), were evaluated. Results revealed that BNP levels were positively correlated with worsening cardiac function and negatively correlated with LVEF. In individuals with obesity or Type 2 diabetes mellitus, BNP levels were unexpectedly lower, whereas patients with chronic kidney disease or atrial fibrillation exhibited elevated BNP levels. A BNP cut-off value of 98.9 was identified, demonstrating high diagnostic sensitivity (91.53%), specificity (83.05%), and accuracy (88.14%). The area under the ROC curve (AUC) indicated strong diagnostic performance for BNP in predicting adverse cardiovascular events. The findings underscore BNP's value not only as a biomarker for diagnosing LHF but also in prognostication and tailoring patient-specific interventions. Future studies should validate these findings across diverse populations to enhance clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.